Osimertinib combined with chemotherapy in patients who had distant recurrence after adjuvant osimertinib for EGFRm resectable SIB-IIIA NSCLC.

Trial Identifier: D5164L00004
Sponsor: AstraZeneca
Start Date: May 2026
Primary Completion Date: May 2030
Study Completion Date: May 2030
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CN Beijing, CN, 100044
CN Beijing, CN, 100021
CN Beijing, CN, 100142
CN Chengdu, CN, 610041
CN chongqing, CN, 400016
CN fuzhou, CN, 350005
CN Fuzhou, CN, 350001
CN guangzhou, CN, 510080
CN Guangzhou, CN, 510289
CN Hangzhou, CN, 310020
CN Hefei, CN, 230022
CN Nanchang, CN, 330006
CN Nanjing, CN, 210009
CN Ningbo, CN, 315010
CN Shanghai, CN, 200030
CN Shenyang, CN, 110042
CN Shenyang, CN, 110004
CN Tianjin, CN, 300060
CN Wuhan, CN, 430022
CN Wuhan, CN, 430030
CN XI'AN, CN, 710004
CN Zhengzhou, CN, 450008